Reconfirmed positive results in veterinary study support path toward market entry
Prenumeration
Beskrivning
| Land | Norge |
|---|---|
| Lista | Oslo Bors |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
Bergen, Norway, 27 August 2025 – Lifecare ASA (LIFE), a MedTech company developing next generation Continuous Glucose Monitoring (CGM) technology for diabetes managment, announces that the second veterinary subject in its ongoing longevity study (LFC-SEN-002) has confirmed the positive findings observed in the first subject.
Summary:
- Data from second subject reconfirms safety, biocompatibility, and suitability for long-term use in ongoing veterinary study LFC-SEN-002.
- Study results build on earlier human data confirming accurate glucose measurement (LFC-SEN-001).
- Longevity study LFC-SEN-002 is still ongoing and planned to continue under extended approval.
- Recent media events force the company to safeguarding shareholder trust through a PFU filing.
Reference is made to Lifecares press release 8 November 2024. The purpose of LFC-SEN-002 is to evaluate sensor efficacy for glucose measurement in dogs and to document longevity, tolerability, and biocompatibility. The previous human study (LFC-SEN-001) demonstrated glucose measurement performance on par with commercially available CGM systems.
The ongoing veterinary longevity study (LFC-SEN-002) focuses on product development aspects, including electronic performance, signal range, radio and Bluetooth connectivity, and power consumption under real-life conditions.
Following 90 days of implantation, histopathological analyses performed by the Norwegian University of Life Sciences (NMBU) confirmed that the device was well tolerated, showing only mild localized tissue reactions consistent with a normal foreign-body response. Importantly, no adverse events were observed, reinforcing evidence that Lifecare’s CGM device is safe and biocompatible for long-term implantation.
The current approval for veterinary studies expires at the end of August. Lifecare has already resubmitted the protocol to secure a continued approval, as LFC-SEN-002 will continue until the company formally defines study end. Additional subjects are planned for enrolment, expanding the scope beyond longevity and tolerability to further validate glucose measurement performance in both healthy and diabetic animals.
Safeguarding shareholder trust throug transparency
In addition to disclosure of positive and re-confirmative study data, this announcement addresses recent media coverage that was based on information Lifecare had refuted with documentation, prior to publication. This media coverage was speculative, inaccurate, and strongly misleading, undermining confidence in the company’s technology and communication. This false, misleading and inaccurate coverage seems to have directly affected the company’s market valuation.
As a publicly listed company, Lifecare has a duty to protect its shareholders by ensuring that accurate and reliable information reaches the market. To safeguard this principle, the company will file a formal complaint with the Norwegian Press Complaints Commission (Pressens Faglige Utvalg, PFU). In Lifecare’s view, the coverage in question failed to meet basic press ethics standards of accuracy and fairness.
Lifecare regards this as a matter of principle—both to protect shareholder value and to uphold trust in transparent market communication.
The company reiterates its strong belief in the future of its technology and its ability to deliver meaningful innovation for people living with diabetes. Entering a defining phase, Lifecare moves forward with confidence — supported by proven results, a solid strategy, and a committed team.